Evaluation of Safety and Performance of the Orbix Breast Lift System
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Oct 15, 2008
Trial Information
Current as of July 21, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- 1.Female subject between 30-50 years of age 2. Subject is referred for mastopexy(breast lifting)due to one of the following reasons:
- • Breast ptosis grade I or II (minimal invasive)
- • Breast ptosis grade I to IV (open procedure)
- • pseudoptosis following breast reduction surgery 3. subject willing to participate as evidenced by signing the written informed consent 4. Minimal invasive: breast cup size \<C
- Exclusion Criteria:
- • 1. Pregnant or lactating women
- • 2. history of surgical procedures involving the ribs and rib cage
- • 3. Osteoporosis
- • 4. breast implants
- • 5. breast carcinoma
- • 6. auto-immune disease -
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Marjoes MP Schuckman, MD
Principal Investigator
Maastricht University Hospital
Adi Cohen
Study Director
Orbix medical
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials